{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:21:11Z","timestamp":1792023671933,"version":"4.4.0"},"reference-count":45,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"unspecified","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2025,9,24]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While anti-interleukin (IL) 5 therapy has been shown to be efficacious to reduce exacerbation rates (ERs) in patients with severe eosinophilic asthma and might also benefit patients with coexisting chronic obstructive pulmonary disease (COPD), it is unknown whether anti-IL5 therapy reduces all types of exacerbations in heterogeneous (smoking) real-life patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults initiating mepolizumab or benralizumab between 2017 and 2019 were identified in Belgian nationwide data. The ER in the year before anti-IL5 therapy initiation was compared to the year after. Exacerbations were classified as severe (hospitalised) exacerbations or moderate (outpatient) exacerbations treated with antibiotics, oral corticosteroids (OCS) or the combination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 807 patients initiating anti-IL5 therapy, severe ER was 40\u00b14 exacerbations per 100 patient years pretreatment versus 17\u00b13 post-treatment initiation (p&lt;0.001, relative risk reduction (RRR) \u221256%, number needed to treat (NNT)=4) and significantly reduced both in patients without COPD (n=616, ER\n                      <jats:sub>pre<\/jats:sub>\n                      =15\u00b12, ER\n                      <jats:sub>post<\/jats:sub>\n                      =6\u00b11, p&lt;0.001, NNT=11) as with coexisting COPD (n=191, ER\n                      <jats:sub>pre<\/jats:sub>\n                      =119\u00b112, ER\n                      <jats:sub>post<\/jats:sub>\n                      =53\u00b19, p&lt;0.001, NNT=2). For moderate exacerbations, ERs were significantly reduced for all types of exacerbations in both patients with or without COPD, except for OCS only-treated exacerbations in patients with coexisting COPD (p=0.288). Current smoking reduced anti-IL5 effectiveness on OCS-treated exacerbations (NNT &gt;1), although current smokers with coexisting COPD still had a great reduction in hospitalisations (ER\n                      <jats:sub>pre<\/jats:sub>\n                      =152\u00b123, ER\n                      <jats:sub>post<\/jats:sub>\n                      =55\u00b118, p&lt;0.001, NNT=1, RRR=-64%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this nationwide cohort study, treatment targeting eosinophilic inflammation was significantly associated with reduced moderate and severe exacerbations, with seemingly less impact on corticosteroid-treated exacerbations in (current smoking) patients with coexisting COPD, but still a large number of hospitalisations were prevented.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2025-003413","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T07:00:24Z","timestamp":1761202824000},"page":"e003413","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Real-life impact of anti-IL5 therapy on exacerbation types in patients with obstructive lung disease"],"prefix":"10.1136","volume":"12","author":[{"given":"Lowie E G W","family":"Vanfleteren","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Clinical Nutrition, University of Gothenburg Sahlgrenska Academy, Gothenburg, Sweden"},{"name":"Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8932-476X","authenticated-orcid":false,"given":"Delphine","family":"Vauterin","sequence":"additional","affiliation":[{"name":"Department of Bioanalysis, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-4363","authenticated-orcid":false,"given":"Lies","family":"Lahousse","sequence":"additional","affiliation":[{"name":"Department of Bioanalysis, Ghent University, Ghent, Belgium"},{"name":"Department of Epidemiology, Erasmus University Rotterdam, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"2026010701513598000_12.1.e003413.1","doi-asserted-by":"crossref","first-page":"101936","DOI":"10.1016\/j.eclinm.2023.101936","article-title":"Global burden of chronic respiratory diseases and risk factors, 1990\u20132019: an update from the Global Burden of Disease Study 2019","volume":"59","author":"Momtazmanesh","year":"2023","journal-title":"eClinicalMedicine"},{"key":"2026010701513598000_12.1.e003413.2","unstructured":"Global initiative for chronic obstructive lung disease (gold) . Global strategy for prevention, diagnosis and management of copd: 2024 report. 2024."},{"key":"2026010701513598000_12.1.e003413.3","unstructured":"Global Initiative for Asthma . Global strategy for asthma management en prevention - update. 2024."},{"key":"2026010701513598000_12.1.e003413.4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00900-2019","article-title":"ERS\/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions","volume":"54","author":"Bourdin","year":"2019","journal-title":"Eur Respir J"},{"key":"2026010701513598000_12.1.e003413.5","doi-asserted-by":"publisher","DOI":"10.1111\/all.15867"},{"key":"2026010701513598000_12.1.e003413.6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/02770903.2022.2036754","article-title":"Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience","volume":"60","author":"Matucci","year":"2023","journal-title":"J Asthma"},{"key":"2026010701513598000_12.1.e003413.7","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jaip.2023.04.029","article-title":"Real-World Effectiveness Study of Benralizumab for Severe Eosinophilic Asthma: ZEPHYR 2","volume":"11","author":"Carstens","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026010701513598000_12.1.e003413.8","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2025.101420","article-title":"Cardiovascular safety of biologic therapies in patients with severe asthma: a nationwide cohort study in Belgium","volume":"57","author":"Van Vaerenbergh","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"2026010701513598000_12.1.e003413.9","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8081122","article-title":"Prevalence of Asthma and COPD and Blood Eosinophil Count in a Middle-Aged Belgian Population","volume":"8","author":"Wijnant","year":"2019","journal-title":"J Clin Med"},{"key":"2026010701513598000_12.1.e003413.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708208"},{"key":"2026010701513598000_12.1.e003413.11","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the Prevention of COPD Exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010701513598000_12.1.e003413.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"2026010701513598000_12.1.e003413.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"2026010701513598000_12.1.e003413.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413181"},{"key":"2026010701513598000_12.1.e003413.15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S2213-2600(19)30338-8","article-title":"Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies","volume":"8","author":"Criner","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026010701513598000_12.1.e003413.16","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/j.jaip.2022.04.034","article-title":"Cigarette Smoking and Asthma","volume":"10","author":"Thomson","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026010701513598000_12.1.e003413.17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200511-1746OC"},{"key":"2026010701513598000_12.1.e003413.18","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201104-0597OC"},{"key":"2026010701513598000_12.1.e003413.19","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2147\/COPD.S294333","article-title":"Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO","volume":"16","author":"Pavord","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026010701513598000_12.1.e003413.20","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200707-973OC"},{"key":"2026010701513598000_12.1.e003413.21","unstructured":"InterMutualistic agency (ima\/aim). Health data; 2024. Available: https:\/\/ima-aim.be\/ [Accessed 7 Oct 2024]."},{"key":"2026010701513598000_12.1.e003413.22","unstructured":"The Minimal Hospital Dataset . Minimale ziekenhuis gegevens (mzg). 2024. Available: https:\/\/www.health.belgium.be\/en\/node\/23607 [Accessed 7 Oct 2024]."},{"key":"2026010701513598000_12.1.e003413.23","unstructured":"Belgian Antibiotic Policy Coordination Commission (BAPCOC) . Belgische gids voor anti-infectieuze behandeling in de ambulante praktijk. 2012. Available: https:\/\/www.bcfi.be\/legacy_assets\/antibioticagids-nl.pdf [Accessed 22 May 2024]."},{"key":"2026010701513598000_12.1.e003413.24","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/MLR.0000000000000729","article-title":"Development of a Claims-based Frailty Indicator Anchored to a Well-established Frailty Phenotype","volume":"55","author":"Segal","year":"2017","journal-title":"Med Care"},{"key":"2026010701513598000_12.1.e003413.25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/ehjqcco\/qcad019","article-title":"Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study","volume":"10","author":"Grymonprez","year":"2024","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026010701513598000_12.1.e003413.26","unstructured":"R: a language and environment for statistical computing. Vienna, Austria, 2022."},{"key":"2026010701513598000_12.1.e003413.27","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(07)61602-x"},{"key":"2026010701513598000_12.1.e003413.28","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2147\/JAA.S474306","article-title":"The Influence of Emphysema on Treatment Response to Biologic Therapy in Severe Asthma","volume":"17","author":"Biener","year":"2024","journal-title":"J Asthma Allergy"},{"key":"2026010701513598000_12.1.e003413.29","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1016\/j.jaip.2023.07.024","article-title":"Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis","volume":"11","author":"Liu","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026010701513598000_12.1.e003413.30","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02119-2019","article-title":"Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD","volume":"55","author":"Mathioudakis","year":"2020","journal-title":"Eur Respir J"},{"key":"2026010701513598000_12.1.e003413.31","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04590-2020","article-title":"Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis","volume":"59","author":"Benson","year":"2022","journal-title":"Eur Respir J"},{"key":"2026010701513598000_12.1.e003413.32","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01393-2017","article-title":"Cigarette smoking and response to inhaled corticosteroids in COPD","volume":"51","author":"Bhatt","year":"2018","journal-title":"Eur Respir J"},{"key":"2026010701513598000_12.1.e003413.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713901"},{"key":"2026010701513598000_12.1.e003413.34","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.18.6891-6903.2000"},{"key":"2026010701513598000_12.1.e003413.35","doi-asserted-by":"publisher","DOI":"10.1096\/fj.00-0432fje"},{"key":"2026010701513598000_12.1.e003413.36","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1164\/ajrccm.153.5.8630596","article-title":"Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking","volume":"153","author":"Pedersen","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"2026010701513598000_12.1.e003413.37","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200304-503OC"},{"key":"2026010701513598000_12.1.e003413.38","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2004.033688"},{"key":"2026010701513598000_12.1.e003413.39","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.57.3.226"},{"key":"2026010701513598000_12.1.e003413.40","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jaip.2023.10.012","article-title":"Tobacco Exposure and Efficacy of Biologic Therapy in Patients With Severe Asthma: A Nationwide Study From the Danish Severe Asthma Register","volume":"12","author":"Baastrup Soendergaard","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026010701513598000_12.1.e003413.41","doi-asserted-by":"crossref","unstructured":"Schleich F , Moermans C , Seidel L , et al . Benralizumab in severe eosinophilic asthma in real life: confirmed effectiveness and contrasted effect on sputum eosinophilia versus exhaled nitric oxide fraction - PROMISE. ERJ Open Res 2023;9. doi:10.1183\/23120541.00383-2023","DOI":"10.1183\/23120541.00383-2023"},{"key":"2026010701513598000_12.1.e003413.42","doi-asserted-by":"publisher","DOI":"10.1111\/all.14514"},{"key":"2026010701513598000_12.1.e003413.43","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1164\/rccm.201908-1550OC","article-title":"Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis","volume":"201","author":"Martinez-Garcia","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026010701513598000_12.1.e003413.44","doi-asserted-by":"crossref","DOI":"10.1186\/s13223-020-00507-0","article-title":"Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts","volume":"17","author":"Ghassemian","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2026010701513598000_12.1.e003413.45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2025-003413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:52:50Z","timestamp":1767779570000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2025-003413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,22]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/bmjresp-2025-003413"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2025-003413","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}